Name | Number of supported studies | Average coverage | |
---|---|---|---|
oligodendrocyte | 14 studies | 32% ± 14% | |
type II pneumocyte | 3 studies | 20% ± 2% |
Insufficient scRNA-seq data for expression of NINJ2 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
breast | 100% | 469.02 | 457 / 459 | 96% | 10.28 | 1072 / 1118 |
lung | 99% | 518.60 | 575 / 578 | 95% | 15.00 | 1094 / 1155 |
intestine | 91% | 153.67 | 882 / 966 | 93% | 6.38 | 490 / 527 |
esophagus | 93% | 187.18 | 1349 / 1445 | 91% | 6.35 | 166 / 183 |
liver | 95% | 320.34 | 215 / 226 | 87% | 9.62 | 352 / 406 |
brain | 85% | 397.39 | 2243 / 2642 | 88% | 9.37 | 619 / 705 |
stomach | 73% | 96.17 | 262 / 359 | 92% | 5.90 | 262 / 286 |
bladder | 86% | 127.81 | 18 / 21 | 73% | 5.60 | 370 / 504 |
skin | 79% | 212.56 | 1432 / 1809 | 77% | 5.17 | 362 / 472 |
uterus | 71% | 101.21 | 121 / 170 | 83% | 8.18 | 382 / 459 |
prostate | 84% | 134.05 | 205 / 245 | 57% | 2.17 | 285 / 502 |
thymus | 79% | 117.52 | 515 / 653 | 49% | 2.30 | 296 / 605 |
ovary | 10% | 12.74 | 18 / 180 | 92% | 10.72 | 396 / 430 |
lymph node | 0% | 0 | 0 / 0 | 100% | 14.79 | 29 / 29 |
spleen | 100% | 444.29 | 241 / 241 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 100% | 11.30 | 1 / 1 |
adipose | 100% | 530.04 | 1202 / 1204 | 0% | 0 | 0 / 0 |
peripheral blood | 100% | 1193.23 | 926 / 929 | 0% | 0 | 0 / 0 |
muscle | 98% | 601.85 | 788 / 803 | 0% | 0 | 0 / 0 |
heart | 97% | 241.99 | 838 / 861 | 0% | 0 | 0 / 0 |
pancreas | 3% | 4.18 | 11 / 328 | 93% | 9.35 | 165 / 178 |
tonsil | 0% | 0 | 0 / 0 | 93% | 7.24 | 42 / 45 |
kidney | 20% | 26.97 | 18 / 89 | 62% | 3.08 | 560 / 901 |
blood vessel | 73% | 119.18 | 969 / 1335 | 0% | 0 | 0 / 0 |
adrenal gland | 33% | 33.45 | 84 / 258 | 20% | 1.02 | 47 / 230 |
eye | 0% | 0 | 0 / 0 | 11% | 0.30 | 9 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0007155 | Biological process | cell adhesion |
GO_0007158 | Biological process | neuron cell-cell adhesion |
GO_0042246 | Biological process | tissue regeneration |
GO_0007399 | Biological process | nervous system development |
GO_0005886 | Cellular component | plasma membrane |
GO_0005515 | Molecular function | protein binding |
Gene name | NINJ2 |
Protein name | Ninjurin-2 (Nerve injury-induced protein 2) Ninjurin 2 Ninjurin 2 (cDNA FLJ52244, weakly similar to Ninjurin-2) |
Synonyms | hCG_25274 |
Description | FUNCTION: Effector of necroptotic and pyroptotic programmed cell death that mediates plasma membrane rupture (cytolysis) (By similarity). Acts downstream of Gasdermin (GSDMA, GSDMB, GSDMC, GSDMD, or GSDME) or MLKL during pyroptosis or necroptosis, respectively: oligomerizes in response to death stimuli and promotes plasma membrane rupture by introducing hydrophilic faces of 2 alpha helices into the hydrophobic membrane, leading to release intracellular molecules named damage-associated molecular patterns (DAMPs) that propagate the inflammatory response (By similarity). Also acts as a homophilic transmembrane adhesion molecule involved in nerve regeneration . Promotes axonal growth . . |
Accessions | ENST00000397265.7 ENST00000433832.2 F5H3L1 ENST00000305108.10 A0A590UJR9 F8WBZ3 Q9NZG7 ENST00000662884.1 B4DNS9 ENST00000542920.1 |